Karyopharm Therapeutics filed for Chapter 11 bankruptcy as part of a plan to merge with Irish hematology biotech, Ayrmid. Massachusetts-based Karyopharm’s financial woes came to a head in August, when ...

Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm for its multiple myeloma and ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has filed for Chapter 11 bankruptcy protection and entered into a restructuring agreement that provides for a proposed merger with Ayrmid Ltd., as the ...

China's NMPA approved golimumab biosimilar ASHULI as the first in China, completing Bio-Thera's unprecedented US-EU-China ...

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) has filed for Chapter 11 bankruptcy protection and entered into a restructuring agreement that provides... Read More ...

Karyopharm files Chapter 11 and names Ayrmid lead bidder in a court-supervised sale. Read how Ayrmid's bid affects its marketed drugs, pipeline and team.

Karyopharm Therapeutics, a commercial-stage pharmaceutical company pioneering novel cancer therapies, has announced that it ...

The Genealogy of the Japanese Pharmaceutical Industry and the Truth of the Drug Discovery Paradigm Shift”[Chapter 4] Drug ...

Now I would like to turn the call over to Heritage Global's Chief Executive Officer, mister Ross Dove. Ross, please go ahead.

Congressional Democrats vowed to put the Trump administration on the defensive with subpoenas and hearings, but said their ...

Detailed price information for Karyopharm Therapeut (KPTI-Q) from The Globe and Mail including charting and trades.

Karyopharm filed for Chapter 11 under a plan to merge with Ayrmid, with competing bids allowed and closing targeted for the ...